European Infrastructure for Translational Medicine


"Translational Research for Innovative Healthcare"

Our vision:

Translate scientific discoveries
into medical products more effectively


What is EATRIS?

EATRIS is a client driven, non-profit organization comprising European academic centers of excellence in translational research. EATRIS transforms scientific discoveries into innovative and high impact medicines, diagnostics and medical devices through European collaborative consortia of academic, industrial and governmental partners.

EATRIS is one of the biomedical infrastructure projects initiated by the European Strategy Forum on Research Infrastructure (ESFRI). In 2013 EATRIS was granted the status of an European Research Infrastructure Consortium (ERIC) by the European Commission. An ERIC is a specific European legal form to facilitate cross-border research through the joint establishment and operation of research infrastructures of European interest.

The Finnish arm of EATRIS is consists of six centers across Finland. The centers contribute to four of the five EATRIS platforms:

- Biomarkers,
- Imaging and Tracers,

- Small Molecules, and
- Advanced Therapy Medicinal Products (ATMP)


Together, they provide a wide range of services to the EATRIS infrastructure in the areas of molecular diagnostic assays, assay development, and production of molecular research and clinical tools, such as imaging, viruses, antibodies, and tracer production.

In addition to their excellence in translational medicine, the EATRIS centers in Finland have key insight into process standardization, regulatory aspects, technology transfer, as well as clinical utilization. Links to the Finnish EATRIS centers can be found under "Centers" in the header section.

To find out how you can benefit from the EATRIS infrastructure, please visit, or continue to the section "How EATRIS works" on this page.    



How EATRIS works


The EATRIS Infrastructure provides a new development pathway, accessible to researchers and companies in need of support for advancing biomedical innovations. EATRIS comprises over 70 leading academic institutions across Europe, each renowned for its individual and high-end research facilities.

The process consists of 4 major steps:

Project Assessment,



As customer you can expect                                                                                                                                            
- Single point of access to the right expertise and facilities
- Expediting the development process
- Access to large and diverse clinical patient cohorts    

News and events


EATRIS Leaflets for download


EATRIS Brochure Biomarkers

EATRIS Brochure Imaging and Tracing


EATRIS Brochure Small Molecules

EATRIS Brochure Vaccines


Selected publications where the EATRIS research infrastructure was used in 2012-2014

Ålgars A, Avoranta T, Österlund P, Lintunen M, Sundström J, Jokilehto T, Ristimäki A, Ristamäki R, Carpén O. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. PLoS One. 2014;9(6):e99590. PMID: 24940619

Avoranta ST, Korkeila E, Ristamäki R, Syrjänen K, Carpén O, Pyrhönen S, Sundström J. ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer. Hum Pathol. 2013;44(6):966-74; PMID: 23332924

Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, Bansal M, Ammad-Ud-Din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K; NCI DREAM Community, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol. 2014 Jun 1. PMCID: PMC24880487

Haapa-Paananen S, Chen P, Hellström K, Kohonen P, Hautaniemi S, Kallioniemi O, Perälä M. Functional profiling of precursor MicroRNAs identifies MicroRNAs essential for glioma proliferation. PLoS One, 2013; 8(4):e60930. PMID: 23577178

Hirvonen T, Suila,  Tiitinen S, Natunen S,  Laukkanen M-L, Kotovuori A, Reinman M, Satomaa T, Alfthan K, Laitinen S, Takkinen K, Räbinä J and  Valmu L (2013) Production of a recombinant antibody specific for i blood group antigen, a mesenchymal stem cell marker. BioResearch Open Access. 2013; 2, 336-345. PMID: 24083089

Honka H, Mäkinen J, Hannukainen JC, Tarkia M, Oikonen V, Teräs M, Fagerholm V, Ishizu T, Saraste A, Stark C, Vähäsilta T, Salminen P, Kirjavainen A, Soinio M, Gastaldelli A, Knuuti J, Iozzo P, Nuutila P. Validation of [18F]FDG and positron emission tomography (PET) for the measurement of intestinal metabolism in pigs, and evidence of intestinal insulin resistance in patients with morbid obesity. Diabetologia. 2013; 56(4): 893-900. PMID: 23334481.

Huhtinen K, Desai R, Ståhle M, Salminen A, Handelsman DJ, Perheentupa A, Poutanen M. Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. J Clin Endocrinol Metab. 2012; 97:4228-35. PMID: 22969138

Huovinen T, Rytkönen K, Lamminmäki U, Pellinen T. A simple heterogeneous one-step assay for screening estrogenic compounds. Biotechnol Lett. 2013;35(1):47-53. PMID:22986538.

Hynninen J, Auranen A, Carpén O, Dean K, Seppänen M, Kemppainen J, Lavonius M, Lisinen I, Virtanen J, Grenman S. FDG PET/CT in staging of advanced epithelial ovarian cancer staging: frequency of supradiaphragmatic lymph node metastasis challenges the traditional concept of disease spread pattern. Gyn. Oncol. 2012;126:64-68. PMID: 22542580

Hyytiä H, Heikkilä T, Brockmann EC, Kekki H, Hedberg P, Puolakanaho T, Lövgren T, Pettersson K. Chimeric recombinant antibody fragments in cardiac troponin I immunoassay. Clin Biochem. 2014; Aug 8. pii: S0009-9120(14)00608-0. PMID: 25111014

Karhunen U, Soikkeli M, Lahdenperä S, Soukka T. Quantitative detection of well-based DNA array using switchable lanthanide luminescence. Anal Chim Acta. 2013;772:87-92. PMID: 23540252.

Kiugel M, Dijkgraaf I, Kytö V, Helin S, Liljenbäck H, Saanijoki T, Yim CB, Oikonen V, Saukko P, Knuuti J, Roivainen A, Saraste A. Dimeric [(68)Ga]DOTA-RGD Peptide Targeting αvβ3 Integrin Reveals Extracellular Matrix Alterations after Myocardial Infarction. Mol Imaging Biol. 2014 Dec;16(6):793-801. PMID: 24984688

Knuuti J, Saraste A. Combined anatomical and functional CT imaging for the detection of coronary artery disease. Eur Heart J Cardiovasc Imaging. 2014 Jan;15(1):106-7. PMID: 24142403

Konsti J, Lundin M, Linder N, Haglund C, Blomqvist C, Nevanlinna H, Aaltonen K, Nordling S, Lundin J. Effect of image compression and scaling on automated scoring of immunohistochemical stainings and segmentation of tumor epithelium. Diagn Pathol. 2012;7:29. PMID: 22436596

Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, Lagström S, Clemente MJ, Olson T, Jalkanen SE, Majumder MM, Almusa H, Edgren H, Lepistö M, Mattila P, Guinta K, Koistinen P, Kuittinen T, Penttinen K, Parsons A, Knowles J, Saarela J, Wennerberg K, Kallioniemi O, Porkka K, Loughran TP Jr, Heckman CA, Maciejewski JP, Mustjoki S. Somatic STAT3 mutations in large granularlymphocytic leukemia. N Engl J Med. 2012;  366(20):1905-13. PubMed PMID: 22591296.

Laajala TD, Corander J, Saarinen NM, Mäkelä K, Savolainen S, Suominen MI, Alhoniemi E, Mäkelä S, Poutanen M, Aittokallio T. Improved statistical modeling of tumor growth and treatment effect in preclinical animal studies with highly heterogeneous responses in vivo. Clin Cancer Res. 2012; 18:4385-96. PMID: 22745104

Laurila PP, Surakka I, Sarin AP, Yetukuri L, Hyötyläinen T, Söderlund S, Naukkarinen J, Tang J, Kettunen J, Mirel DB, Soronen J, Lehtimäki T, Ruokonen A, Ehnholm C, Eriksson JG, Salomaa V, Jula A, Raitakari OT, Järvelin MR, Palotie A, Peltonen L, Oresic M, Jauhiainen M, Taskinen MR, Ripatti S. Genomic, Transcriptomic, and Lipidomic Profiling Highlights the Role of Inflammation in Individuals With Low High-density Lipoprotein Cholesterol. Arterioscler Thromb Vasc Biol. 2013;33(4):847-57. PMID: 23413431

Lehtinen L, Ketola K, Mäkelä R, Mpindi JP, Viitala M, Kallioniemi O and Iljin K. High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget 2013;4(1):48-63. PMCID: PMC3702207

Leinonen V, Rinne JO, Wong DF, Wolk DA, Trojanowski JQ, Sherwin PF, Smith A, Heurling K, Su M, Grachev ID. Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. Acta Neuropathol Commun. 2014;2:46. PMID: 24755237

Leivonen SK, Sahlberg KK, Mäkelä R, Due EU, Kallioniemi O, Børresen-Dale AL, Perälä M. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol, 2014; 8(1):93-104.

Li XG, Helariutta K, Roivainen A, Jalkanen S, Knuuti J, Airaksinen AJ. Using 5-deoxy-5-[18F]fluororibose to glycosylate peptides for positron emission tomography. Nat Protoc. 2014; 9(1):138-45. PMID: 24356772

Linder N, Konsti J, Turkki R, Rahtu E, Lundin M, Nordling S, Haglund C, Ahonen T, Pietikäinen M, Lundin J. Identification of tumor epithelium and stroma in tissue microarrays using texture analysis. Diagn Pathol. 2012;7:22. PMID: 22385523

Linder N, Turkki R, Walliander M, Mårtensson A, Diwan V, Rahtu E, Pietikäinen M, Lundin M, Lundin J. A malaria diagnostic tool based on computer vision screening and visualization of Plasmodium falciparum candidate areas in digitized blood smears. PLoS One. 2014; 9(8):e104855. PMID: 25144549

Pemovska T, Johnson E, Kontro M, Repasky G, Chen J, Wells P, Cronin C, McTigue M, Kallioniemi O, Porkka K, Murray B, Wennerberg K. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature, in press, 2014.

Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013; 3(12):1416-29. PMID: 24056683

Rinne JO, Wong DF, Wolk DA, Leinonen V, Arnold SE, Buckley C, Smith A, McLain R, Sherwin PF, Farrar G, Kailajärvi M, Grachev ID.[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol. 2012;124(6):833-45. PMID: 23053137

Roivainen A, Hautaniemi S, Möttönen T, Nuutila P, Oikonen V, Parkkola R, Pricop L, Ress R, Seneca N, Seppänen M, Yli-Kerttula T. Correlation of [18F]FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. Eur J Nucl Med Mol Imaging. 2013;40(3):403-10. PMID: 23229747

Sampo M, Tarkkanen M, Tukiainen E, Popov P, Gustafson P, Lundin M, Böhling T, Blomqvist C, Lundin J. A web-based prognostic tool for extremity and trunk wall soft tissue sarcomas and its external validation. Br J Cancer. 2012; 106(6):1076-82. PMID: 22353813

Sándor GK, Tuovinen VJ, Wolff J, Patrikoski M, Jokinen J, Nieminen E, Mannerström B, Lappalainen OP, Seppänen R, Miettinen S. Adipose Stem Cell Tissue-Engineered Construct Used to Treat Large Anterior Mandibular Defect: A Case Report and Review of the Clinical Application of Good Manufacturing Practice-Level Adipose Stem Cells for Bone Regeneration. J Oral Maxillofac Surg 2013;71(5),938-950. PMID: 24558162

Snellman A, Rokka J, Lopez-Picon FR, Eskola O, Wilson I, Farrar G, Scheinin M, Solin O, Rinne JO, Haaparanta-Solin M. Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2012; 39:1784-95. PMID: 22801729

Stedt H, Samaranayake H, Pikkarainen J, Määttä AM, Alasaarela L, Airenne K, Ylä-Herttuala S. Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide. Gene Ther. 2013;20(12):1165-71. PMID: 24067866

Tarkia M, Saraste A, Saanijoki T, Oikonen V, Vähäsilta T, Strandberg M, Stark C, Tolvanen T, Teräs M, Savunen T, Green MA, Knuuti J, Roivainen A. Evaluation of 68Ga-labeled tracers for PET imaging of myocardial perfusion in pigs. Nucl Med Biol 2012;39:715-723. PMID: 22264857

Turkki P, Makkonen KE, Huttunen M, Laakkonen JP, Ylä-Herttuala S, Airenne KJ, Marjomäki V. Cell susceptibility to baculovirus transduction and echovirus infection is modified by protein kinase C phosphorylation and vimentin organization. J Virol. 2013;87(17):9822-35. PMID: 23824807

Tuppurainen L, Sallinen H, Kokki E, Koponen J, Anttila M, Pulkkinen K, Heikura T, Toivanen P, Hämäläinen K, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S. Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer. Hum Gene Ther Clin Dev. 2013;24(1):29-37. PMID: 23692381.

Wolff J, Sándor GK, Miettinen A, Tuovinen VJ, Mannerström B, Patrikoski M, Miettinen S. GMP-level adipose stem cells combined with computer-aided manufacturing to reconstruct mandibular ameloblastoma resection defects: Experience with three cases. Ann Maxillofac Surg. 2013 Jul;3(2):114-25. PMID: 24205470

Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, Majumder MM, Malani D, Murumägi A, Knowles J, Porkka K, Heckman C, Kallioniemi O, Wennerberg K, Aittokallio T. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.  Sci Rep, 2014;4: 5193. PMID: 24898935